Meeting Coverage


Gastrointestinal Cancers Symposium

New Standard of Care for Refractory Metastatic Colorectal Cancer

Significant improvement in OS, PFS with addition of bevacizumab to trifluridine/tipiracil

GiCS over a photo of the Moscone Convention Center West in San Francisco, California

Latest GICS Meeting Coverage

'More Is Not Better' in Two First-Line Trials for Biliary Tract Cancer

No survival benefit with three-drug chemo regimen or clear PFS gain with anti-PD-L1/bevacizumab

January 22, 2023
New First-Line Standard for Metastatic Pancreatic Cancer

Liposomal irinotecan regimen boosts outcomes, although expert expressed concern about toxicity

January 22, 2023
Adding Targeted Drug to Chemo Boosts Survival in Gastric/GEJ Cancer

Longest overall survival reported to date with the addition of zolbetuximab to chemotherapy

January 21, 2023
Perioperative Chemo Matches Multimodal Tx for Locally Advanced Esophageal/GEJ Cancer

Nearly identical 3-year survival, questioning the need for radiotherapy before surgery

January 20, 2023
GICS Roundup: PD-1 Inhibitor Yields 100% Response Rate in dMMR Rectal Cancer

Plus: Promising activity in BRAF-mutant CRC, L-asparaginase drug falls short in pancreatic cancer

January 24, 2022
Adagrasib Promising in KRAS-Mutant GI Cancers

The KRAS G12C inhibitor showed a disease control rate of 100% in small study

January 24, 2022
Survival Bump in Biliary Cancer With Immunotherapy Plus Chemotherapy

Adding durvalumab boosts OS by 1.3 months, first survival improvement in a decade

January 23, 2022
Immunotherapy Not Additive to Standard of Care for Untreated Metastatic CRC

No difference in survival outcomes with add-on nivolumab to chemo, bevacizumab

January 23, 2022
Potential New First-Line Options for Unresectable Hepatocellular Carcinoma

Tremelimumab-durvalumab improves OS, single-agent durvalumab non-inferior to sorafenib

January 22, 2022
Pre-Op Immunotherapy Combo Makes Headway in Select Gastric Cancers

Plus, novel bispecific antibody tested as first-line therapy for advanced gastric/GEJ cancer

January 21, 2022
More Data for Upfront PD-1 Inhibition in Gastric, Esophageal Cancer

Updates from two landmark trials show consistent benefits across subgroups, PD-L1 expression

January 21, 2022
Preop RT Flunks Test in Borderline Pancreatic Cancer

Chemotherapy alone judged efficacious but not chemoradiation

January 20, 2021
Drug Hits Target in Advanced Biliary Cancer

Responses in up to a third of patients with FGFR inhibitor infigratinib

January 19, 2021
Liquid Biopsy Predicts Colon Cancer Relapse Months Before CT

Test for ctDNA outperformed existing biomarker, may help guide therapy

January 17, 2021


GiCS Future Focus
February 2023
GiCS Video Pearls
January 2023